Home › Funds › Spruce Street Capital LP › KNSA
Spruce Street Capital LP position in KNSA
KINIKSA PHARMACEUTICALS INTL · Health Care
Spruce Street Capital LP reported holding 918,070 shares of KNSA (KINIKSA PHARMACEUTICALS INTL) in its Q3 2026 13F filing — a position valued at US$68.5M, representing 10.89% of its reported portfolio and ranking #1 among its reported holdings. Spruce Street Capital LP has disclosed KNSA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Spruce Street Capital LP's KNSA position evolved
Spruce Street Capital LP first disclosed a stake in KNSA in Q4 2025 at 434,982 shares (US$17.9M). The position peaked in Q3 2026 at 918,070 shares, worth US$68.5M. Across 4 filings, Spruce Street Capital LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 918,070 shares valued at US$68.5M. Notable position changes include a 75% increase in Q1 2026 (shares rose 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 434.98K | $17.94M | New |
| Q1 2026 | 761.06K | $36.65M | Add |
| Q2 2026 | 918.07K | $58.71M | Add |
| Q3 2026 | 918.07K | $68.50M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KNSA and 13F data
KNSA (KINIKSA PHARMACEUTICALS INTL) is a Health Care company. 49 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), BAKER BROS. ADVISORS LP (US$181.3M), TANG CAPITAL MANAGEMENT LLC (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KNSA
- Rubric Capital Management LP 4.00M sh · $255.79M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $181.28M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 2.26M sh · $144.52M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 624.93K sh · $39.96M · Q2 2026
- ORBIMED ADVISORS LLC 420.60K sh · $26.90M · Q2 2026
- Penn Capital Management Company, LLC 347.66K sh · $25.97M · Q3 2026
- Soleus Capital Management, L.P. 246.35K sh · $15.75M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 202.02K sh · $15.07M · Q3 2026
- ArrowMark Colorado Holdings LLC 215.55K sh · $13.78M · Q2 2026
More on Spruce Street Capital LP
FAQ
How long has Spruce Street Capital LP held KNSA?
Spruce Street Capital LP has disclosed KNSA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Spruce Street Capital LP's current position in KNSA?
As of Q3 2026, Spruce Street Capital LP holds 918.07K shares of KNSA (KINIKSA PHARMACEUTICALS INTL), valued at $68.50M, representing 10.89% of its reported portfolio and ranking #1.
Has Spruce Street Capital LP been buying or selling KNSA?
In the latest 13F filing (Q3 2026), Spruce Street Capital LP held unchanged its position in KNSA. The position peaked in Q3 2026 at 918.07K shares.
Which other funds hold KNSA?
Other major institutional holders of KNSA include Rubric Capital Management LP, BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.